HC Wainwright restated their hold rating on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Monday, AnalystRatings.com reports.
Separately, Zacks Investment Research downgraded shares of Evoke Pharma from a buy rating to a hold rating in a report on Wednesday, October 23rd.
NASDAQ:EVOK opened at $1.59 on Monday. The stock has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $0.89. The stock has a market capitalization of $40.22 million, a price-to-earnings ratio of -3.46 and a beta of 1.86. Evoke Pharma has a 1 year low of $0.50 and a 1 year high of $3.26.
An institutional investor recently bought a new position in Evoke Pharma stock. Citadel Advisors LLC purchased a new position in shares of Evoke Pharma Inc (NASDAQ:EVOK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 59,047 shares of the specialty pharmaceutical company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned approximately 0.25% of Evoke Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.57% of the company’s stock.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Featured Story: How to build a Fibonacci channel
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.